Effect of Paliperidone on Patients with First-episode Schizophrenia
WANG Hao;LIU Sheng-wu;Basic medical college of Wuhan University;
Objective: To investigate the effects of Paliperidone on patients with first-episode schizophrenia, and to examine the effects in levels of serum interleukin-1β(IL-1β), IL-2, IL-6 and brain-derived neurotrophic factor(BDNF). Methods: Eighty patients with first-episode schizophrenia were enrolled in the schizophrenic group, and were treated with Paliperidone for eight weeks. The levels of Serum IL-1β, IL-2, IL-6 and BDNF were measured with enzyme linked immunosorbent assay(ELISA) in 60 healthy volunteers(normal control group) and the schizophrenic group. The symptoms of patients were measured with positive and negative syndrome scale(PANSS), and the PSP scale was used to assess their social function. Results: The PANSS score of schizophrenic group was(94.17±16.34) before the treatment, and was(46.09±12.52) at the 8th week of the treatment. Sixty-eight cases were cured, 10 cases were significantly improved, and 2 cases were improved. Similarly, the PSP score of schizophrenic group was(47.94 ±10.88) before the treatment, and was(68.23 ±17.65) at the 8th week of the treatment. The scores of social beneficial activities and disrupt and aggression were significantly different after therapy(P0.01). Before the treatment, the serum levels of IL-1β、IL-2 and IL-6 in the schizophrenic group were significantly higher than those in the normal control group(P0.01), and the serum levels of BDNF in the schizophrenic group was lower than that in the normal control group(P0.05). The serum levels of IL-1β and IL-2in the schizophrenic group were significantly decreased after the treatment(P0.01), and the serum level of BDNF in the schizophrenic group was significantly increased after the treatment(P0.05). There was a positive correlation between the IL-2 level and the PANSS positive symptom scores before the treatment(r=0.551,P0.05), and a positive correlation between the BDNF level of and the PSP scores after the treatment(r=0.692,P 0.05).Conclusion: Schizophrenic patients present a state of immune activation.